This review explores the many barriers to accessing lipid-lowering therapies (LLTs) for the prevention and management of atherosclerotic cardiovascular disease (ASCVD). Geographical, knowledge, and regulatory barriers significantly impede access to LLTs, exacerbating disparities in healthcare infrastructure and affordability. We highlight the importance of policy reforms, including pricing regulations and reimbursement policies, for enhancing affordability and streamlining regulatory processes. Innovative funding models, such as value-based pricing and outcome-based payment arrangements, have been recommended to make novel LLTs more accessible. Public health interventions, including community-based programs and telemedicine, can be utilized to reach underserved populations and improve medication adherence. Education and advocacy initiatives led by patient advocacy groups and healthcare providers play a crucial role in raising awareness and empowering patients. Despite the barriers to access, novel LLTs present a big opportunity to reduce the burden of ASCVD, emphasizing the need for collaborative efforts among policymakers, healthcare providers, industry stakeholders, and patient advocacy groups to address these barriers to improve access to LLTs globally.
Reducing low-density lipoprotein cholesterol (LDL-C) levels is crucial to the prevention of atherosclerotic cardiovascular disease (ASCVD). However, many patients, especially those at very high ASCVD risk or with familial hypercholesterolemia (FH), do not achieve target LDL-C levels with statin monotherapy. The underutilization of novel lipid-lowering therapies (LLT) globally may be due to cost concerns or therapeutic inertia. Emerging approaches have the potential to lower LDL-C and reduce ASCVD risk further, in addition to offering alternatives for statin-intolerant patients. Shifting the treatment paradigm towards initial combination therapy and utilizing novel LLT strategies can complement existing treatments. This review discusses innovative approaches including combination therapies involving statins and agents like ezetimibe, bempedoic acid, cholesterol ester transfer protein (CETP) inhibitors as well as strategies targeting proprotein convertase subtilisin/kexin type 9 (PCSK9) and angiopoietin-like protein 3 (ANGPTL3) inhibition. Advances in nucleic acid-based therapies and gene editing are innovative approaches that will improve patient compliance and adherence. These strategies demonstrate significant LDL-C reductions and improved cardiovascular outcomes, offering potential for optimal LDL-C control and reduced ASCVD risk. By addressing the limitations of statin monotherapy, these approaches provide new management options for elevated LDL-C levels.
The prevalence of diabetes mellitus (DM) during pregnancy is rising globally, yet data on gestational diabetes mellitus (GDM) in South Africa remain limited. This study retrospectively analysed glycaemic characteristics and outcomes in 298 women with pre-gestational DM and hyperglycaemia first detected in pregnancy (HFDP) between August 2019 and January 2021. Hyperglycaemic disorders were attributed to GDM (39.6%, n = 118), followed by type 2 diabetes (T2DM) (29.2%, n = 87), overt DM (22.1%, n = 66) and type 1 diabetes (T1DM) (9.1%, n=27). Significant risk factors for GDM included family history, obesity, poor obstetric history, and a previous history of macrosomia in pregnancy. Glycated haemoglobin (HbA1c) levels at booking were highest in women with pre-gestational DM (8.8% in T1DM and 7.8% in T2DM). A combination of HbA1c ≥ 5.75% and fasting plasma glucose (FPG) of 5.1-6.9 mmol/L was the most accurate method for diagnosing GDM, with an area under the curve (AUC) of 0.93. Postpartum follow-up using an oral glucose tolerance test (OGTT) revealed that 21% of women with GDM developed DM, while 53% had an impaired glucose tolerance (IGT). However, only 48% of those with GDM were followed up postpartum, highlighting the significant challenge of loss to follow-up. These findings emphasise the growing prevalence of HFDP and the elevated risk of postpartum DM, highlighting the need for improved follow-up care to mitigate long-term complications. Additionally, the combination of FPG and HbA1c ≥ 5.75% shows promise for enhancing GDM diagnosis and screening protocols, particularly in developing countries. Further research is needed to validate these findings and assess their broader applicability.